pembrolizumab,tislelizumab,lenvatinib,sorafenib,rivoceranib,camrelizumab
merck,beigene,jiangsu hengrui pharmaceuticals,elevar therapeutics,bayer,eisai,novartis
['rationale-301', 'leap-002']
ready for proferred paper session: leap-002, shr-1210-310, and rationale-301 #esmo22 
Reborn. ?ID @whyes . ??????????????????
??? **??** ??????????